Abu Dhabi: The Abu Dhabi Health Services Company (SEHA), a subsidiary of PureHealth, and Sanofi have signed a collaboration agreement to advance diagnostic performance and accuracy in the field of rare diseases. The agreement will focus on accelerating the screening procedure for lysosomal storage disorders (LSDs) and reducing the average diagnostic journey for rare disease patients.
Sanofi, in collaboration with SEHA, will utilize its extensive expertise in disease pathways to expedite the generation and application of clinical knowledge for the accurate diagnosis of patients with lysosomal storage disorders (LSDs).
Furthermore, Sanofi will offer a comprehensive suite of sponsored services to enhance patient access to an early and precise diagnosis. Additionally, the company will provide training to SEHA’s healthcare professionals (HCPs) on sample collection procedures and best practices.
Mr. Jean-Paul Scheuer, MCO Lead and Specialty Care General Manager, commented that “the journey to rare disease diagnosis is a long one, given that such diseases can be difficult to identify and given the many gaps prevalent in the local diagnostic system. Through our collaboration with SEHA, Sanofi aims to fundamentally transform the rare disease diagnostics landscape in the UAE by removing the barriers and delays in the diagnosis of LSD patients and improving their access to effective treatment and care.”
“As the Emirate of Abu Dhabi reimagines healthcare by embracing digital transformation and a patient-first approach, we recognize that building high-impact alliances with regional and global healthcare innovators is crucial to elevating the standard of care and delivering cutting-edge preventive, diagnostic, and treatment options to the people of our nation,” Mr. Saeed Jaber Al Kuwaiti, Group Chief Executive Officer of SEHA, remarked.